

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Obecabtagene autoleucl for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

| |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
| No. |
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
| N/A |
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
| N/A |
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made? |
| N/A |

Approved by Associate Director (name): Jasdeep Hayre **Date:** 4
September 2024